International Journal of Research in Engineering and Applied Sciences(IJREAS)
Available online at http://euroasiapub.org/journals.php
Vol. 13 Issue 7, July -2023,
ISSN(O): 2249-3905, ISSN(P) : 2349-6525 | Impact Factor: 8.202| Thomson Reuters ID: L-5236-2015

Systemic Immune modulation changes correlate with clinical features in early stage Human Lung Cancer

[1]Afreen Siddique, [2] Dr. Jyotsna
[1]Research Scholar, [2]Research Supervisor
Department of Biotechnology, NIILM University, Kaithal, Haryana

Abstract

Immune system dysfunction is linked to the development of cancer. Regarding the clinical significance of dysregulated immune system in early "non-small cell lung cancer (NSCLC)", there is uncertainty. The primary data was provided by hospitalized patients with diagnosis of oral and lung cancer who were visited during the research period. Patients whose records were retrieved for the record survey were not invited to participate in interviews. To choose hospital respondents for the study, a simple random selection technique was used. Our findings demonstrated a notable dysregulation of the immune response in the early stages of non-small type carcinoma of the lung, which was shown by a decrease in total lymphocytes, "CD3+ T cells, HLA-DR− CD3+ T cells, CD4+ T cells, and NKT cells". Nonetheless, there was an increase in a number of lymphocyte subsets, including "HLA-DR+ CD3+ T cells and CD38+ lymphocytes". To sum up, our research revealed multiple striking dysregulations of the systemic immune system in early NSCLC. Furthermore, we found that clinical characteristics closely linked to "NSCLC treatment and prognosis is correlated with systemic immune dysregulation in NSCLC patients".

Keywords:*systemic immune dysregulation, lymphocyte, prognosis, hospital, lung cancer.*

Introduction

There is a correlation between the clinical characteristics of early "non-small cell lung tumors (NSCLC)" and dysregulated immune system functioning. Studies show that this kind of disorder is accompanied with a substantial reduction in T cells, NKT cells, dormant T cells, total lymphocytes. These and CD4+ T cells, among other immune cell types. This study emphasizes the possible role that regional immunological dysfunction may have in the occurrence of cancer and suggests that it is an interesting area for future research given the correlation between it and the advancement of cancer. Furthermore, research has looked at the relationship to the national immunological activation and the clinical manifestations of NSCLC, revealing differences in leukocyte subsets based on factors like age, gender, smoking status, and cancer subtype. This research sheds light on the intricate relationship between immune dysregulation and the clinical characteristics of early NSCLC, providing valuable insights for understanding and potentially targeting this aspect of the disease. Systemic immune dysregulation refers to a state in which the immune system is not functioning properly, leading to an imbalance in the control of immune responses. This can result in an overactive or underactive immune system, which can contribute to the development of various diseases, including autoimmune diseases and some cancers. In the context of cancer, systemic immune dysregulation has been linked to cancer progression and may have clinical implications for "early non-small cell lung cancer (NSCLC)". Systemic immune dysregulation can have various causes, leading to an imbalance in the

immune system's function. Some common causes include genetic mutations, such as in the FOXP3 gene causing IPEX syndrome, can lead to dysfunctional regulatory T cells and autoimmune diseases like diabetes mellitus and eczema. These factors highlight the diverse range of causes that can disrupt the normal functioning of the immune system, leading to systemic immune dysregulation and its associated health implications.

Materials and methods

Both patients and donors in good health: New patients were sourced from the Second Affiliated Hospital who had undergone surgical resection and had no prior medical history. Control peripheral blood samples were supplied by "34 healthy donors", "all of whom tested negative for HIV, hepatitis B, hepatitis C, and syphilis-related antibodies. 34 patients with non-advanced NSCLC made up the discovery group, and 292 individuals with the same illness made up the validation group".

Setting Up Cells for Flow Cytometry: The antibodies against HLA-DR (L243), "CD45 (HI30), CD3 (UCHT1), CD4 (RPA-T4), CD8a (RPA-T8), CD38 (HB-7), CD16 (3G8)", and CD56 (HCD56) that were used in this work were provided by "BioLegend. PB lymphocytes were produced when red blood cells were lysed using a lysing solution (BD Pharm Lyse). PB mononuclear cells (PBMCs) (1 × 106/ml) in phosphate-buffer (PBS), 2% fetal bovine serum, and 0.1% (w/v) sodium azide were preincubated with FcgIII/IIR-specific antibody at 4°C for 15 minutes in order to avoid non-specific binding and facilitate staining with fluorochrome-coupled antibody combinations. The data were collected using BD Biosciences' FACSCanto II and FACSFortessa flow cytometry devices, and then they were examined using FlowJo software (Tree Star)".

"The Subsets of Lymphocytes: Total lymphocytes (CD45+ SSC-low), activated lymphocytes (CD38+ CD45+), T lymphocytes (CD3+ CD45+), B lymphocytes, natural killer cells (NK cells), natural killer cells (NKT cells), T helper cells (CD4+ CD3+ CD45+), T cytotoxic cells (CD8+ CD3+ CD45+), activated T lymphocytes (HLA-DR+ CD3+ CD45+), and resting T lymphocytes (HLA-DR+ CD3+ CD45+)". A summary of the immunophenotyping assessment was done on cancer patients and healthy people.

Results and Discussion

In patients, the proportion of B lymphocytes was notably greater in those at the T1 stage compared to those at the T2 stage (Figure 1.A). We then examined the relationship across SID along with N stage in NSCLC. The proportions of "CD38+ CD45+ leukocytes" were larger in the PB of patients lacking lymphatic metastases, with a p-value of 0.0604 (Figure 1.B). The percentage of "CD4+ T" cells along with NK cells was greater in individuals with lymphatic metastases ($p = 0.0596$) as seen in Figures 1.C and D. In individuals having the advanced TNM stage, there was a noticeable decrease in the proportion of B cells ($p = 0.0716$) (Figure 1.E).

We conducted a detailed analysis of the relationship across SID along with the NSCLC TNM stage based on pathological subtypes. We first examined the connection across SID along with the TNM stage of LUSC. LUSC individuals who had lymphatic metastases showed considerably elevated proportions of CD3+ and CD4+ T lymphocytes (Figures 1.F, G). The proportions of "CD4+ T cells" were consistently greater in advanced-stage LUSC patients, as shown in Figure 1.H. Conversely, individuals who had advanced LUSC



exhibited a notably reduced NK cell percentage (Figure 1.I).

Figure:1. Correlation across SID along with cancer stage. Analyzed the SID inside the validation group to

explore the link across SID along with the stage of NSCLC. The TNM stage is determined according to the 8th version of the Manual for IASLC tumour stages. a bar graph showing the percentage of B lymphocytes is displayed in each T stage in the peripheral blood of those with NSCLC. There are 207 individuals in group T1, 36 in group T2, 18 in group T3, and 15 in group T4. (B–D) A line graph showing the percentage of NK cells (D), CD4+ T cells (C), and activated lymphocytes (B) determined from lymphatic metastases in the peripheral blood of those with advanced NSCLC. N+ denotes the presence of lymphatic metastases with a sample size of 46, while N- indicates lymphatic metastasis-negative with a sample size of 235. "A bar graph illustrating the proportion of B lymphocytes in the PB of individuals with NSCLC based on TNM stage. Early stage includes 242 cases with TNM I and II, whereas advanced stage includes 38 cases with TNM III and IV. A bar diagram illustrating the proportion of CD3+ T cells (F) along with CD4+ T cells (G) inside the PB of LUSC patients based on lymphatic metastasis. N+ indicates positive lymphatic metastasis with a sample size of 16, whereas N- indicates negative lymphatic metastasis with a sample size of 27. A bar plot displays the proportion of CD4+ T cells (H) along with NK cells (I) inside the PB of LUSC patients based on TNM stage. Early stage: TNM I+II, 32 cases; advanced stage: TNM III+IV, 11 cases. The ordered pair is (J, K). Bar plot showing the proportion of CD3+ T cells (J) along with resting T lymphocytes (K) inside the PB of LUAD patients based on T stage. T1 has a sample size of 187; T2 has a sample size of 16; T3 has a sample size of 12; T4 has a sample size of 8. Left Bar graph illustrating the proportion of B cells inside the PB of LUAD patients based on lymphatic metastasis. Data is presented as mean ± SEM; N+ refers to lymphatic metastasis positive with a sample size of 25; N- refers to lymphatic metastasis-negative with a sample size of 198. NS indicates no statistical significance; *P < 0.05, **P<0.01".

Conclusion

The present investigation revealed a correlation across the structureic immune status of NSCLC patients and clinical characteristics counting "age, sex, smoking history, body weight, and pathological categories". In early NSCLC, these characteristics also correlate with immune checkpoint inhibition. A correlation was also identified across the structureic immune status of patients and various aspects concerning the future outlook and management of NSCLC, "counting tumor stage, differentiation, pathological characteristics, surgical procedures, complications, and perioperative SIRS".

Reference

1. Thommen, D.S., Koelzer, V.H., Herzig, P. *et al.* A transcriptionally and functionally distinct PD-1^{+} CD8^{+} T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. *Nat Med* **24**, 994–1004 (2018). https://doi.org/10.1038/s41591-018-0057-z
2. O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S. Function of human tumor-infiltrating lymphocytes in early-stage non–small cell lung cancer. Cancer immunology research. 2019 Jun 1;7(6):896-909.
3. Chen PY, Wu CY, Fang JH, Chen HC, Feng LY, Huang CY, Wei KC, Fang JY, Lin CY. Functional change of effector tumor-infiltrating CCR5+ CD38+ HLA-DR+ CD8+ T cells in glioma microenvironment. Frontiers in immunology. 2019 Oct 9;10:2395.
4. Christopoulos P, Gaipl US. Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation. Frontiers in Oncology. 2023 Apr 3;13:1182081.

5. Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences. 2017 May 9;114(19):4993-8.
6. Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E., ... &Maccalli, C. (2023). Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications. *Advances in Cancer Biology-Metastasis*, 100107.
7. Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Translational lung cancer research. 2015 Apr;4(2):177.